In line with the SCOR group’s policy of diversifying its capital protection tools, SCOR Global Life SE, the subsidiary of SCOR SE encompassing SCOR’s worldwide Life & Health reinsurance operations, announces its i
At its Investors’ Day today, 4 September 2013, SCOR presents its new three-year strategic plan covering the period mid-2013 to mid-2016.
The 28th SCOR Global Life Medical Symposium was held in Paris on Thursday 25 June 2013.
SCOR's first half of 2013 results.
SCOR announces the public release and the filing with the Autorité des marches financiers of its interim financial report for the six months ended 30 June 2013.
SCOR records net income of EUR 189 million in the first half 2013, despite high Nat Cat activity, a continued low yield environment and equity impairments.
In this paper, we consider the valuation of the Guaranteed Minimum Withdrawal Benefit (GMWB) option associated with a variable annuity insurance policy.
The classical Critical Illness (CI) product has become a standard and mature product offered in many markets around the world. The recent decade has seen a search towards the next generation of product design.
Red blood cell disorders occur as a result of a lack, an excess or a genetic defect in the production of these vital cells. A shortage of red blood cells, or erythrocytes, is evidenced by anaemia.
Red blood cell disorders occur as a result of a lack, an excess or a genetic defect in the production of these vital cells. A shortage of red blood cells, or erythrocytes, is evidenced by anaemia.
Red blood cell disorders occur as a result of a lack, an excess or a genetic defect in the production of these vital cells. A shortage of red blood cells, or erythrocytes, is evidenced by anaemia.
The 27th SCOR Global Life Medical Symposium took place on Thursday 6 December 2012.
